射频联合电针除皱在面部年轻化美容术中的应用

目的:探讨将射频技术联合电针除皱应用于面部年轻化美容的临床效果.方法:对皮肤松弛或皱纹明显的面部老化者,分别或联合应用射频除皱术和微针电子除皱术进行治疗.射频除皱采用深圳GSD公司GP699A型射频皮肤治疗仪.能量密度50～100J/cm2,频率2M-8M,6次为一个疗程,每次治疗间隔10天;电针除皱采用英国ERP Face Magic电子美容除皱仪,电流强度1.0mA～20.0mA,每次30分钟,疗程及间隔时间同射频治疗组;联合治疗组先行射频除皱治疗,五天后再进行电针除皱,疗程及间隔时间同上.结果:178例面部皮肤老化者,行单纯射频除皱58例,单纯电针除皱49例,二者联合治疗71例.其中射频治疗组总有效率为84%,半年有效维持率49%;电针治疗组总有效率78%,半年有效维持率42%;联合治疗组总有效率为96%,半年有效维持率72%,显著高于任何单一治疗组.结论:射频技术联合电针除皱即能改善面部浅表皱纹又能收缩面部肌肉促进其紧缩,具有起效快、效果显著、疗效持久的特点,是面部年轻化美容的理想方法.     

拉米夫定联合胸腺肽α1治疗慢性重型乙型肝炎临床观察

目的:观察拉米夫定联合胸腺肽α1治疗慢性重型乙型肝炎的疗效.方法:22例慢性重型乙型肝炎患者在综合性护肝治疗基础上,加服拉米夫定100mg,每天1次;同时皮下注射胸腺肽α1针1.6 mg,每周3次,疗程4～12周.结果:治疗前后患者肝功能明显改善,血清总胆红素水平从(326±189)μmol/L降至(36±16.2)μmol/L,丙氨酸转氨酶水平从(367±289)U/L降至(21±7.5)U/L,凝血酶原时间从(31±11.5)秒缩短至(15±3)秒.有16例患者治疗前检测到HBV DNA,其中10例治疗后阴转(低于1×102copies/ml),其余6例无明显变化(持续105～106 copies/ml).22例患者存活18例,总有效率81.8%.结论:拉米夫定联合胸腺肽α1治疗慢性重型乙型肝炎有效.     

国产两性霉素B漱口治疗儿童血液恶性肿瘤化疗后口腔白斑的安全性和有效性观察

目的观察国产两性霉素B溶液漱口在治疗或预防口腔白斑的安全性和有效性。方法选取2016年1月～2018年7月在我中心住院的发生口腔白斑的恶性血液肿瘤患儿30例,国产两性霉素B25 mg溶于500 mL灭菌注射用水漱口,5～6次/d。记录患儿使用两性霉素B漱口前后肝肾功能、血钾水平,以及每日口腔白斑变化情况。疗效评价标准:治愈:白斑完全消失;显效:白斑缩小50%,但未完全消失;进步:白斑缩小50%;无效:白斑无改善或加重。结果 30例患儿使用两性霉素B漱口,用药时长范围1～30 d,中位时间9.5 d,治愈22例(73.3%),显效6例(20%),进步0例(0%),无效2例(6.7%),总体有效率为93.3%。两性霉素B溶液用于儿童恶性肿瘤患儿化疗后口腔黏膜炎漱口安全性可,未见加重肝肾功能损害,未出现血钾进一步降低,无明显相关不良事件。结论两性霉素B溶液用于儿童恶性肿瘤患儿化疗后口腔黏膜炎漱口安全有效,无明显相关不良事件。     

腔内治疗下肢动脉硬化闭塞症的临床研究

目的:下肢动脉硬化闭塞症(arteriosclerosis obliterans,ASO)是血管外科常见疾病,我们拟讨论腔内成形术在ASO治疗中的应用.方法:回顾2008年5月至2010年4月我科收治的76例ASO病例,对手术成功率、手术效果和糖尿病等合并症对疗效的影响进行分析.结果:总体技术成功61例,技术成功率80.3%,FontaineⅡ期组技术成功36例(成功率92.3%),明显高于Ⅲ期(82.1%)和Ⅳ期组(22.2%);合并糖尿病组22例(28.9%),技术成功15例(成功率68.2%),低于无糖尿病组的85.2%;结论:腔内成形术是治疗ASO的有效微创手术方法,积极腔内手术干预有助提高早期患者成功率,同时对晚期患者可有效改善症状.     

低剂量氯吡格雷治疗不稳定型心绞痛的疗效观察

目的:探讨氯吡格雷(泰嘉)治疗不稳定型心绞痛(unstable angina pectoris,UAP)的疗效。方法:102例不稳定型心绞痛患者随机分治疗组(60例)和对照组(42例),治疗组在常规药物的基础上加氯吡格雷50mg,每天1次,连用4周。对照组用常规药物治疗。两组均观察心绞痛的发作次数、24h动态心电图。结果:治疗组显效43例(79.6%),有效5例(9.3%),对照组显效23例(48.0%),有效10例(20.8%),两组相比差异有显著性(p<0.05)。治疗组心绞痛的发作次数与对照组比较明显减少(P<0.01)、24h动态心电图与对照组比较明显改善(P<0.01)。结论:UAP患者在常规药物治疗的基础上联用低剂量氯吡格雷可取得良好效果,且安全性好。     

阿泰宁治疗肠易激综合征50例的疗效观察

目的 观察和评价阿泰宁（含酪酸梭菌CGMCC NO.0313-1株）治疗肠易激综合征（IBS）的临床疗效.方法 对符合罗马Ⅱ诊断标准的IBS患者,用阿泰宁胶囊口服,1次3粒,1天2次,疗程14～21 d.治疗期间观察患者的症状变化、服药情况,治疗结束后评价药物的疗效.结果 50例IBS患者治疗后的腹泻或便秘等症状有显著的改善（P＜0.05）.治愈率为62%（31/50）,总有效率为94%（47/50）,治疗中未见不良反应或副作用.结论 阿泰宁是治疗IBS的一种安全有效的微生态药品,不但短期应用效果好,而且慢性腹泻或便秘患者可长期服用.     

Q开关532 nm与755 nm激光治疗咖啡斑的疗效对比

本中心回顾性研究咖啡斑患者84例,随机给予Q开关532 nm和755 nm激光治疗,观察临床效果。结果显示,Q开关532 nm激光治疗36例,痊愈10例(27. 8%),显效10例(27. 8%),有效8例(22. 2%),无效8例(22. 2%); Q开关755 nm激光治疗48例,痊愈14例(29. 2%),显效13例(27. 1%),有效11例(22. 9%),无效10例(20. 8%),84例患者总有效率78. 6%。术后半年随访,色素沉着9例,色素减退3例,复发9例。Q开关激光治疗形状不规则的咖啡斑有效率为79. 5%,治疗形状规则的咖啡斑有效率为52. 5%,两组治疗的有效率差异有统计学意义(P <0. 05),Q开关532 nm激光和Q开关755 nm激光对咖啡斑的治疗效果无显著的统计学差异(P> 0. 05)。以上结果表明,Q开关532 nm激光和Q开关755 nm激光对咖啡斑有明确的治疗效果,且外形不规则的咖啡斑治疗效果好。     

特发性右心室流出道室性心律失常射频消融术后复发因素分析

目的:探讨特发性右心室流出道室性心律失常射频消融术后,患者室性心律失常复发的原因,旨在为进一步降低复发率提供线索。方法:1999年12月至2009年12月,在解放军总医院老年心血管内科住院行导管射频消融的特发性右心室流出道室性心律失常患者共145例(男55例,女90例),治疗终点为室性心律失常消失,不能被心室电刺激和静滴盐酸异丙肾上腺素诱发,术后1天复查动态心电图并电话随访观察疗效。结果:在145例患者中,即刻成功136例,成功率为93.8%。随访23.8±6.7月,共有9例患者复发,复发率为6.62%。9例复发患者再次行射频消融术的靶点局部激动(34.0±7.6 ms)明显早于第一次射频消融术(30.4±8.5 ms)(P<0.05);靶点起搏与自发心律失常体表心电图QRS波形的符合数(11.8±0.45)大于第一次射频消融术(11.1±0.78)(P<0.05);复发患者第一次手术在最早激动点处单极标测r波的出现比例大于第二次手术(P<0.05),再次手术均成功。结论:导管射频消融治疗特发性右心室流出道室性心律失常是有效、可行的方法。靶点标测欠精确是术后复发的主要原因。     

一种新型国产内镜射频消融治疗仪对胃食管反流病的疗效

目的:探讨一种新型国产内镜射频消融治疗仪对胃食管反流病(GERD)的疗效。方法:选取2016年6月-2017年6月来我院就诊的难治性GERD患者50例,随机分为内镜射频治疗组(美顿Medi誖射频治疗仪,n=25)与药物治疗组(n=25)。比较两组患者干预前后的酸反流严重程度、胃食管反流病自测量表(GerdQ)评分、质子泵抑制剂(PPI)的药物使用率、简明健康调查量表(SF-36)评分。结果:(1)内镜射频治疗组患者干预后即刻的胃镜提示射频消融治疗区域的消化道黏膜出现收缩、增厚,干预后6、12个月分别有15例(60.0%)、20例(80.0%)的食管下段黏膜的充血带较前减少。(2)两组干预后3、12个月的GerdQ总分均显著低于干预前(P0.05),内镜射频治疗组干预后3、12个月的GerdQ总分均显著低于同期药物治疗组(P0.05)。(3)全部患者干预前均需要药物来缓解症状,内镜射频治疗组干预3、12个月时的PPI药物使用率均显著低于药物治疗组(P0.05)。(4)内镜射频治疗组干预后SF-36的生理职能、生命活力、精神状态、总体健康等维度评分均显著高于同期药物治疗组(P0.05)。结论:美顿Medi?射频治疗仪对GERD患者是一种安全、有效的治疗选择,能显著改善反流症状,减少PPI药物使用,提高患者的生活质量。     

宫腔镜对剖宫产疤痕缺损治疗方法研究

目的:探讨宫腔镜治疗剖宫产疤痕缺损的临床效果,寻找剖宫产疤痕缺损治疗的有效方法。方法:将我院确诊的60例剖宫产疤痕缺损的患者随机等分为两组,对照组患者实施药物保守治疗,实验组患者实施宫腔镜治疗,比较两组患者的治疗效果。结果:实验组患者实施宫腔镜治疗后,患者的月经期均有明显缩短,阴道不规则流血消失,行经时间及月经量均少于对照组患者(P<0.05)。结论:对剖宫产疤痕缺损的患者采用宫腔镜治疗可取得较好的治疗效果,其能够有效改善患者的临床症状,值得在临床应用。     

比亚芬对微等离子体治疗疤痕术后创面修复的临床观察

目的：对比观察比亚芬对微等离子体术后创面修复的临床疗效.方法：将46例需进行微等离子体治疗的萎缩性痤疮瘢痕患者随机分成2组,治疗组31例术后即刻外用比亚芬,对照组15例术后不使用任何药物.结果：治疗组的红斑消退时间、痂皮脱落时间、创面愈合时间明显快于对照组,P〈0.05,差异有统计学意义.结论：比亚芬对微等离子体术后的创面愈合有明显的促进作用.     

微等离子束对豚鼠皮肤超微结构分析和羟脯氨酸测定

目的观察微等离子束对豚鼠皮肤胶原组织作用效应的组织学和超微结构变化及羟脯氨酸含量测定,探讨微等离子束的作用机理。方法选择15只豚鼠,每只豚鼠背部划分为实验侧和空白对照侧2个等分区域,给予60W/10 kJ微等离子束照射,于作用后即刻、1周后和1月后分别切取实验侧及空白对照部位皮肤行组织病理维多利亚-立春红染色,透射电镜分析和羟脯氨酸检测试剂盒进行含量测定。结果 60 W/10 kJ即刻表现为表皮局灶性出现点阵状改变,部分表皮出现汽化缺失或者坏死变性,真皮浅层胶原组织出现点阵化表现和明显均质化;特殊染色显示微等离子束主要影响真皮胶原纤维,形成局灶性胶原纤维凝集和变性。1周后皮肤浅层胶原组织结构逐渐致密,排列有序,有少量组织细胞。1月后皮肤浅层胶原组织明显增厚,胶原纤维增粗并排列致密,弹力纤维呈局灶性增粗。透射电镜显示微等离子束作用后表皮细胞较完整,细胞间结构正常,但真皮胶原丧失正常结构,细胞结构消失,大量细胞凋亡明显,1月后仍可见少量细胞凋亡的表现但胶原结构逐渐恢复,浅层胶原纤维排列明显致密。羟脯氨酸测定显示微等离子束作用1周后羟脯氨酸含量要高于作用之前,但是差异性不具有统计学意义（P〉0.05）;1月后羟脯氨酸含量要明显高于作用前,差异性具有统计学意义（P〈0.05）。结论微等离子束对豚鼠皮肤胶原组织作用有明显的刺激效应,其主要靶组织为真皮胶原组织,可以明显促进皮肤新生胶原的增生。     

Intralesional cryotherapy for enhancing the involution of hypertrophic scars and keloids

Although therapeutic management of hypertrophic scars and keloids using contact or spray cryosurgery has yielded significant improvement or complete regression of hypertrophic scars and keloids, it requires one to 20 treatment sessions. This study was designed to assess the clinical safety and efficacy of an intralesional needle cryoprobe method in the treatment of hypertrophic scars and keloids.Ten patients, ranging in age from 3 to 54 years, with a total of 12 hypertrophic scars and keloids of more than 6 months duration and of diverse causes, were included in this study. The 18-month trial evaluated volume reduction of the hypertrophic scars and keloids after a single session of intralesional cryotherapy. Objective (hardness and color) and subjective (pain/tenderness and itchiness/discomfort) parameters were examined on a scale of 0 to 3 (low score was better). Pretreatment and posttreatment histomorphometric studies of the collagen fibers included spectral picrosirius red polarization and fast Fourier transformation orientation index. A specially designed cryo-needle was inserted into the long axis of the hypertrophic scars and keloids so as to maximize the volume of the hypertrophic scars and keloids to be frozen. The cryo-needle was connected by an adaptor to a cryogun filled with liquid nitrogen, which was introduced into the cryoprobe, thereby freezing the hypertrophic scars and keloids. After the hypertrophic scars and keloids were completely frozen, the cryoprobe defrosted and was withdrawn.An average of 51.4 percent of scar volume reduction was achieved after one session of intralesional cryosurgery treatment (average preoperative hypertrophic scars and keloids volume, 1.82 +/- 0.33; average posttreatment volume, 0.95 +/- 0.21; p < 0.0022). Significant alleviation of objective and subjective clinical symptoms was documented. Mild pain or discomfort during and after the procedure was easily managed. Only mild local edema and epidermolysis, followed by a short reepithelialization period, were evident. During the 18-month follow-up period, there was no evidence of bleeding, infection, adverse effects, recurrence, or permanent depigmentation. The histomorphometric analysis demonstrated rejuvenation of the treated scars (i.e., parallelization) and a more organized architecture of the collagen fibers compared with the pretreated scars.This study demonstrated the increased efficacy of this method as a result of increased freezing area of deep scar material compared with that obtained with contact/spray probes. As a result, fewer treatment cycles are needed. Because the reepithelialization period is short, treatment intervals, if any, can be shortened to 2 to 3 weeks. This intralesional cryoneedle method is simple to operate and safe to use, it necessitates less postoperative care of the wound, and it can easily be added to any preexisting cryosurgical unit.     

Effect of Mederma on hypertrophic scarring in the rabbit ear model

Currently accepted conservative treatments of hypertrophic scars are limited to steroid injections, radiation therapy, and silicone occlusive therapy. However, the use of Mederma for these problematic lesions has become quite prevalent in the clinical setting. Little scientific evidence exists to support the efficacy of this product in reducing hypertrophic scars. The aim of this study was to study the effects of Mederma on hypertrophic scars in the rabbit hypertrophic scar model, allowing the histologic quantification of scar elevation, dermal collagen organization, vascularity, and inflammation and the gross examination of scar erythema. Full-thickness wounds down to cartilage, four per ear, were created in four New Zealand White rabbits, for a total of 32 scars. Twenty-eight days after the initial wounding, the hypertrophic scars were photographed, and treatment of half of the scars on each ear was begun with Mederma three times per day for a total of 4 weeks. The untreated scars served as control scars and were left exposed to air. After 4 weeks of treatment, the scars were once again photographed. The rabbits were then killed, and the scars were analyzed histologically. The pretreatment and posttreatment photographs were compared by using computer quantification of magenta, yellow, and cyan expression within the scars.Histologic analysis demonstrated no significant reduction in scar hypertrophy or scar elevation index. However, a significant improvement in dermal collagen organization was noted on comparing Mederma-treated scars with untreated control scars (p < 0.05). No significant difference in dermal vascularity or inflammation was noted. Computer analysis of the scar photographs demonstrated no significant reduction in scar erythema with Mederma treatment. The active product in Mederma, allium cepa, has as its derivative quercetin, a bioflavonoid noted for its antiproliferative effects on both normal and malignant cells, and its antihistamine release effects. These properties could theoretically prove beneficial in reversing the inflammatory and proliferative responses noted in hypertrophic scars. Despite the authors' inability to demonstrate a reduction in scar hypertrophy, the improvement in collagen organization noted in the Mederma-treated scars suggests it may have an effect on the pathophysiology of hypertrophic scar formation.     

康莱特注射液配合化疗对肝癌的治疗效果及免疫细胞活性的影响

目的:观察康莱特注射液联合化疗对肝癌患者的临床疗效及其对患者自身免疫细胞活性的影响。方法:收集150例确诊为肝癌的患者,随机平均分为对照组与治疗组。其中对照组患者采用西医方案进行化疗,治疗组在对照组的基础上给予康莱特注射液配合治疗,连续治疗2个月后,观察两组患者治疗前后的近期疗效、体重变化、生活质量改善、化疗毒性反应、患者治疗1、3、5年后的生存率及对免疫细胞活性的影响。结果:对照组与治疗组近期总有效率分别为44%、68%,治疗组显著高于对照组;对照组与治疗组患者生活质量改善率分别为33.3%、66.7%,治疗组显著高于对照组;治疗前后对照组与治疗组的体质量变化好转率分别为21.3%、24%,差异不显著;对照组患者治疗1、3、5年后的生存率明显低于治疗组;治疗组患者在治疗后,免疫力明显提升,两组患者治疗后各免疫学指标相比差异显著;对照组化疗毒性反应明显高于治疗组。结论:采用康莱特注射液联合化疗可以明显提高肝癌患者的治疗效果与免疫细胞的活性,有效缓解患者的临床症状,提高生活质量,明显降低化疗药物的不良反应。     

Treatment of keloids by surgical excision and immediate postoperative single-fraction radiotherapy

The authors report the outcomes of patients with keloid scars treated with a protocol of extralesional excision and immediate single-fraction adjuvant radiotherapy. The design of the study was a retrospective analysis with up to 5-year outcome data. The setting was a single treatment team, University Teaching Hospital in London, United Kingdom. Participants (n = 80) were treated for 80 keloid scars (59 percent female patients, 76 percent nonwhite), and 44 percent of keloids were located on earlobes. For all patients, prior treatment without radiotherapy had failed. The salvage treatment reported in this article is combined extralesional excision and immediate postoperative external-beam radiotherapy. A 10-Gy dose of superficial 60-kV or 100-kV photon irradiation was given within 24 hours of the operation. The main outcome measure was freedom from recurrence of keloid scars. Results were that all keloid scars were controlled at 4-week follow-up. Probability of relapse at 1 year was 9 percent; at 5 years, probability of relapse was 16 percent. The earlobe showed no greater chance of relapse than other sites on the body. The authors' report shows that extralesional excision of keloid followed by early, single-fraction, postoperative radiotherapy is both simple and effective in preventing recurrence at excision sites.     

Low-dose enalapril in the treatment of surgical cutaneous hypertrophic scar and keloid--two case reports and literature review

Hypertrophic scars and keloids are 2 forms of excessive cutaneous scarring that occur in predisposed individuals. The healing process varies greatly among patients, and the risk of a bad scar evolution is unpredictable. Keloids create disfiguring scars with associated erythema and pain or pruritus or restricted range of motion, and are a major cause of morbidity. A fortuitous observation was made by the first author of this study who, at age 54, developed an erythematous and painful postsurgical abdominal keloid scar after undergoing left colectomy for colon adenocarcinoma. Four months later, after treatment with low-dose enalapril (10 mg, once a day) for mild arterial hypertension, her keloid scar rapidly improved and she eventually made a complete recovery. second case involved a 70-year-old female with diabetes who was affected by a long-standing postsurgical abdominal keloid scar of 2 years' duration. She was intentionally treated with the same low dose of enalapril, and, after 6 months of therapy, the bad scar showed marked improvement. We conducted an exhaustive search of the literature pertaining to the wound healing process, specifically to determine whether angiotensin-converting enzyme (ACE) inhibitors have a healing effect on wounds. ACE inhibitors are known to induce reduction of left ventricular collagen content and to attenuate remodeling during the postinfarctual period (thus improving ventricular function), and they have been shown to exert a pulmonary antifibrotic effect. After conducting this literature search, it became apparent that no data on cutaneous scars and ACE inhibitors are available. During the posttraumatic or postoperative stage, it is useful to achieve the best possible aesthetic results and to decrease the risk of a disfiguring keloid scar, thereby avoiding revision surgery; to this purpose, an early treatment with a low dose of enalapril is a possible solution, even if further confirmatory observations are needed.     

HIFU治疗子宫腺肌病142例的临床疗效分析（附12例妊娠病例）

目的：评价高强度聚焦超声（highintensityfocusedultrasound,HtFU）治疗子宫腺肌瘤的临床疗效及安全性。方法：选取2007年12月--2012年12月在我院行H删治疗的142例子宫腺肌病患者,治疗后连续1、3、6、12个月随访,评价患者病灶的超声影像学变化及临床症状的改善情况。结果：治疗后,有效随访118例,彩超检查显示治疗后第1个月子宫体积平均缩小35％,第3个月缩小59％,第6个月缩小85％,第12个月缩小80％。110例经量增多的子宫腺肌病患者中,3例在治疗后12个月经量恢复正常水平,45例在治疗后12个月经量明显减少,基本恢复正常值,68例在治疗后12个月经量较治疗前明显减少,但仍高于正常值;2例在治疗后12个月经量变化不大,总有效率为98．3％。118例痛经的子宫腺肌病患,34例在治疗后随访的12个月内痛经消失,80例在治疗后随访的12个月内仍有轻度痛经,4例在治疗后随访的12个月内仍有中度以上痛经,总有效率为96．6％。随访过程中发现12例再妊娠病例。结论：HIFU治疗子宫腺肌病具有安全,有效,并发症少的特点,且不影响患者妊娠,能够满足患者保留子宫、再生育的需求。可作为一种无创治疗子宫腺肌病的有效治疗方法。     

X-irradiation reduces lesion scarring at the contusion site of adult rat spinal cord

Spinal cord injury (SCI) results in cell death and tissue destruction, and ultimately cavitation followed by the formation of lesion scars at the injury site. The lesion scars include an astrocytic component (glial scar) and a fibroblastic component (connective tissue scar). The purpose of the present study is to determine if X-irradiation could minimize the formation of lesion scars and reduce the levels of chondroitin sulfate proteoglycans (CSPGs) in the contusion SCI model of the adult rat. Two weeks after SCI, a connective tissue scar formed at the injury site consisting primarily of fibroblasts and exhibits strong CSPG immunoreactivity. The fibroblasts might originate from the connective tissue of pia mater or arachnoid mater. At the same time, reactive astrocytes in the spared tissue accumulate surrounding the lesion cavity to form a thick glial scar with significant enhancement of glial fibrillary acidic protein (GFAP) and CSPG immunoreactivity. After X-irradiation (40 Gy) of the injury site 2 days post-injury, that results in an attenuated dose to the lesion, the connective tissue scar was not observed, and accordingly, almost no CSPG immunoreactivity was detected at this area. Meanwhile, the glial scar and its CSPG immunoreactivity were prominently reduced. X-irradiation did not show significant improvement in locomotor recovery, but resulted in a slight delay of body weight recovery following injury. This preparative treatment could be used to reduce secondary scarring in the lesion resulting in an enriched site for further treatment such as growth related transplantation.     

Nd：YAG1064nm激光、伊曲康唑治疗轻中度甲真菌病近期疗效分析

目的 观察Nd：YAG1064nm激光治疗机、伊曲康唑治疗甲真菌病的有效性及安全性.方法 选取符合入组条件的患者60例,病甲共125个.将60例患者随机分为A、B两组,A组予以Nd：YAG1064nm激光治疗;B组予以伊曲康唑口服治疗.每组均于第8周、第16周、第24周时随访,随访时予以真菌学评价及临床疗效评价.结果 A组第8周、16周、24周有效率分别为78.9％、52.6％、52.6％,B组第8周、16周、24周有效率分别为80.9％、66.2％、67.6％.A、B两组临床疗效差异无统计学意义（P＞0.05）.结论 激光治疗甲真菌病疗效肯定,且元不良反应.在轻中度甲真菌病患者中,激光治疗和药物治疗有效率差异不大.